Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This is the Abstract from the Asco 2020 Annual Meeting....Background:
MCY-M11 is a mesothelin-targeting chimeric antigen receptor (CAR) therapy made by a non-viral, mRNA-based platform, for rapid ( < 1 day) CAR manufacturing. We are conducting a phase I dose escalation trial in ovarian cancer and malignant peritoneal mesothelioma (MPM) (NCT03608618).
Methods:
MCY-M11 are fresh, non-expanded, autologous peripheral blood mononuclear cells (PBMCs) transfected by flow electroporation with mRNA encoding a human anti-mesothelin CAR. Following a 3+3 design, patients are treated in dose level (DL) escalating cohorts (DL1 1.0 x 107, DL2 5.0 x 107, DL3 1.0 x 108, DL4 5.0 x 108 cells/dose), in one cycle of weekly x 3 doses, intraperitoneal (ip) without preconditioning chemotherapy.
Results:
By January 2020, CP-M11-101 study successfully completed DL1 and DL2 without safety concerns. Based on 11 patients treated in DL1, DL2 and DL3, ip infusion of MCY-M11 is safe and well tolerated. No infusion-related adverse events and no dose limiting toxicities (DLTs) have occurred. No neurotoxicity has been observed. Most reported treatment-related adverse events have been Grades 1-2 per NCI CTCAE. One patient in DL3 presented with G2 pericarditis, fever and transient neutropenia clinically assessed as related SAEs, that resolved without further complications. These events were assessed as on-target off-tumor effects and possibly G1 cytokine release syndrome (CRS). Two unrelated SAEs (G2 confusion in a patient in DL2; G3 enterocutaneous fistula in a patient in DL3) were reported. These 2 patients have been replaced as they did not complete the evaluation period (3 weekly infusions and the DLT 43 day follow up). There have been no treatment-related discontinuations or deaths. Three patients in DL2 showed stable disease (SD) by RECIST 1.1 at the end of the DLT period. Of them, 1 completed the study and did not participate in additional follow up, 1 remained in SD 6 months, and 1 remained in SD 2 months. In DL3, 1 patient remains in SD at 2 months, and evaluation is pending for the other 2 patients. Enrollment is ongoing.
Conclusions:
Feasibility of 1-day manufacturing of MCY-M11 for ip delivery is demonstrated. Treatment has been safe. Initial SD observed in DL2 and DL3 with one-cycle infusions is encouraging and supports exploration of additional strategies such as the addition of preconditioning chemotherapy and multiple cycles to increase efficacy. Clinical trial information: NCT03608618.
https://www.trinitydelta.org/wp-content/uploads/2020/05/MaxCyte-Outlook-200526.pdf
MaxCyte: entering the sweet spot
Cell therapies are expected to become a major new class of therapeutic agent; and MaxCyte’s unrivalled expertise with flow electroporation puts it right at the heart of it. The strategic decision a decade ago to invest in and develop this now key enabling technology is set to pay off. MaxCyte’s ExPERT equipment range, coupled with proven processing skills, has resulted in a stream of collaborative partnerships with cell therapies’ leading players. Potential pre-commercialisation milestones now exceed $800m. The proprietary CARMA clinical programme is also reaching a pivotal moment and is expected to become self-financing by end-2021. We have updated our model to reflect the progress achieved, and £23.6m raise, which results in a valuation of £260m, equivalent to 340p a share.
Hi all,
Short results video with Doug Doerfler - https://youtu.be/VPKrYpcBVfw
Commenting on the annual results, Doug Doerfler, CEO of MaxCyte, said: "2019 was a year of outstanding progress across all areas of our business. Our Life Sciences business continued to exhibit strong growth, reflecting MaxCyte's leadership as an enabler of next-generation cell-based therapies and resulting in a period of financial outperformance.
"Over the year we maintained progress with our lead CARMA candidate, MCY-M11, which is advancing through a Phase I clinical trial, demonstrating the feasibility of our one-day cell therapy manufacturing process. We remain fully committed to the MCY-M11 clinical development programme, though are prepared for an impact on timelines due to delays caused by COVID-19 restrictions. In March 2020, dosing in the 4(th) cohort commenced according to schedule and at the higher dosing level. I am really proud of this achievement and would like to thank everyone involved in the trial to date.
"With unprecedented restrictions in place due to COVID-19, we remain mindful of the potential impact on revenues through slowdowns in customer operations or delays in clinical trials. However, we remain confident that MaxCyte has a resilient business model underpinned by strong recurring revenues and prospects for continued growth.
"We have every reason to remain highly optimistic for the future. I believe we will continue to see long-term momentum in MaxCyte's business as a whole and, notwithstanding the COVID-19 situation, I look forward to updating the market with our continued positive progress."
Morning. Short TV interview with Doug Doerfler following yesterday's results:
www.fmp-tv.co.uk/company/maxcyte-investor-videos-and-news/
MaxCyte's presentation from our 11th July London growth company seminar is now available in our members area here: https://www.sharesoc.org/members-area/
Morning. Short TV clip following this mornings results: www.vimeo.com/263050642/fbede3e592
Morning - short TV clip following this weeks results: http://fmp-tv.co.uk/company/maxcyte-investor-videos-and-news/
Wow! Excellent RNS- using CRISPR gene editing to correct the faulty gene in sickle cell disease and at the same time tackling DNA mutations. "Using MaxCyte's Proprietary GT® System, MaxCyte and its collaborators at the National Heart, Lung and Blood Institute (NHLBI) and National Institute of Allergy and Infectious Diseases (NIAID) demonstrated successful CRISPR-induced corrections of the mutation behind SCD in more than 30 percent of patient-derived B cells" Technology is in its infancy but the potential in a whole range of conditions is mind boggling. http://www.investegate.co.uk/maxcyte--inc---mxct-/rns/presentation-of-positive-preclinical-data/201704250700121821D/
How's that healthy profit doing now?
Now down around 30% from year high.
...and quiet on here....gave me a chance to top up this morning at 250p.......I expect the herd are off gallivanting elsewhere!....brilliant!
...and quiet on here....gave me a chance to top this morning at 250p.......I expect the herd are off gallivanting elsewhere!....brilliant!
so few posts on here, which is a good thing!.......watch and learn how a good company can go under the radar until the big boys have to take notice, my investment is showing a healthy profit in a month!
Thanks. In the end bought some through the cheaper broker I sometimes use.
Up another now!11% again.......a good share to be in
Strange one that!......If you look under directors dealings on HL you will see some have been buying MXCT.....other than that just give them a ring!
Maxcyte are not listed on HL website. Does anyone know what (Di/s) before (MXCT) means?
This is an underrated share with few posts......just like PRSM...keep it quiet....plenty of upside as todays RNS will prove!
Morning, short TV interview for Maxcyte's results announced this morning http://fmp-tv.co.uk/company/maxcyte-investor-videos-and-news/
Morning, Short TV clip on last week's MaxCyte IPO: www.fmp-tv.co.uk/company/maxcyte-investor-videos-and-news/
AIM Securities in Issue The number of shares in issue is 43,470,461. The percentage of shares not in public hands is 66.97%. The following lists all holdings of 3% or larger. Shareholder Shares Percentage Intersouth Partners VI, L.P. 8,238,108 18.95% Bost-Jackson, LLC 4,650,207 10.70% Harbert Venture Partners 3,691,223 8.49% Legal & General Inv Mgmt Ltd 3,500,000 8.05% Blackrock Inv Mgmt (UK) Limited 2,142,857 4.93% River and Mercantile Asset Mgmt Ltd 2,142,857 4.93% Unicorn AIM VCT 2,142,857 4.93% MASA Life Sciences Ventures, LP 1,853,879 4.26% http://www.maxcyte.com/news/investors-content.php
I'm in:-P